Triple combination of pegylated interferon alpha 2b, ribavirin and amantadine for treatment of chronic hepatitis

被引：0
|
作者：
Younossi, ZM
McCullough, AJ
Barnes, DS
Post, A
Ong, JP
Mullen, KD
Carey, WD
O'Shea, R
Levinthal, G
Gramlich, T
Martin, LM
Bringman, D
Tavill, A
Ferguson, R
机构：
来源：
GASTROENTEROLOGY | 2003年 / 124卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(03)83944-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A781 / A781
页数：1
相关论文
共 50 条
  • [21] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Kainuma, Mosaburo
    Furusyo, Norihiro
    Kajiwara, Eiji
    Takahashi, Kazuhiro
    Nomura, Hideyuki
    Tanabe, Yuichi
    Satoh, Takeaki
    Maruyama, Toshihiro
    Nakamuta, Makoto
    Kotoh, Kazuhiro
    Azuma, Koichi
    Shimono, Junya
    Shimoda, Shinji
    Hayashi, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (35) : 4400 - 4409
  • [22] Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    Mosaburo Kainuma
    Norihiro Furusyo
    Eiji Kajiwara
    Kazuhiro Takahashi
    Hideyuki Nomura
    Yuichi Tanabe
    Takeaki Satoh
    Toshihiro Maruyama
    Makoto Nakamuta
    Kazuhiro Kotoh
    Koichi Azuma
    Junya Shimono
    Shinji Shimoda
    Jun Hayashi
    World Journal of Gastroenterology, 2010, 16 (35) : 4400 - 4409
  • [23] Pegylated interferon α2a plus ribavirin versus pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    Berenguer, J.
    Gonzalez-Garcia, J.
    Lopez-Aldeguer, J.
    Von-Wichmann, M. A.
    Quereda, C.
    Hernando, A.
    Sanz, J.
    Tural, C.
    Ortega, E.
    Mallolas, J.
    Santos, I.
    Miralles, P.
    Montes, M. L.
    Bellon, J. M.
    Esteban, H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) : 1256 - 1263
  • [24] Pegylated interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C genotype
    Hasan, F
    Asker, H
    Al-Khaldi, J
    Siddique, I
    Owaid, SF
    Al-Ajmi, M
    Al-Nakib, B
    HEPATOLOGY, 2003, 38 (04) : 629A - 629A
  • [25] Treatment of Chronic Hepatitis with Sofosbuvir in Combination with Ribavirin with or without Pegylated Interferon
    Sidhu, Sandeep S.
    Malhi, Nirmaljeet
    Singh, Rupinder
    Gover, Rajiv
    Sidhu, Js
    Bansal, Ajesh
    Goyal, Omesh
    Sidhu, Gursewak
    Nanda, Vijay
    Saluja, Harmeet
    Sehgal, Alok
    Simran, Sidhu
    Kishore, Harsh
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S383 - S383
  • [26] Preliminary treatment results of liver transplant recipients with recurrent hepatitis C virus nonresponsive to interferon alpha2B and ribavirin using combination pegylated interferon alpha 2B with ribavirin.
    Neff, GW
    Montalbano, M
    Lee, YM
    Slapak, G
    Safdar, K
    Morrero, R
    Nery, J
    Weppler, D
    Demodina, M
    Schiff, E
    Tzakis, A
    HEPATOLOGY, 2002, 36 (04) : 183A - 183A
  • [27] Treatment of chronic hepatitis delta with pegylated interferon-α2b
    Erhardt, Andreas
    Gerlich, Wolfram
    Starke, Christine
    Wend, Ulrike
    Donner, Andreas
    Sagir, Abdurrahman
    Heintges, Tobias
    Haeussinger, Dieter
    LIVER INTERNATIONAL, 2006, 26 (07) : 805 - 810
  • [28] Pegylated interferon alpha 2b induces less thyroid dysfunction than standard interferon alpha 2b in the treatment of chronic hepatitis C
    Patel, Y
    Chapalamadugu, R
    Ramdhaney, S
    Baradarian, R
    Iswara, K
    Tenner, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : S87 - S88
  • [29] Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus
    Hashimoto, Yuki
    Kanto, Hiromi
    Itoh, Masatoshi
    JOURNAL OF DERMATOLOGY, 2007, 34 (08): : 577 - 582
  • [30] Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis CA Meta-Analysis
    Nicolas Flori
    Natalie Funakoshi
    Yohan Duny
    Jean-Christophe Valats
    Michael Bismuth
    Dimitri Christophorou
    Jean-Pierre Daurès
    Pierre Blanc
    Drugs, 2013, 73 : 263 - 277
12345